An innovative development company with a new approach to orbital atherectomy
Cardio Flow is developing a new atherectomy device for removing or modifying plaque—including calcified and fibrotic plaque—in a wide range of vessel sizes.
Meeting a critical clinical need
Atherosclerosis is a highly common medical condition in which certain arteries are blocked by plaque, which restricts the vital flow of blood to a part of the body, usually in the heart, legs, and neck.
Atherectomy devices are designed to remove this plaque—the device is inserted through the patient’s artery to cut away or abrade the blockage and restore blood flow.
Cardio Flow’s FreedomFlow® technology may potentially provide physicians with a more flexible, efficient way to treat both soft and calcified plaque in a variety of vessel sizes. It is currently undergoing clinical testing for treatment of blockages in the peripheral arteries.
An extensive intellectual property portfolio
Cardio Flow, Inc., founded in 2014, has developed an extensive intellectual property portfolio for this new technology, including 44 issued U.S. patents, 2 pending U.S. patents, and 6 published U.S. patents—plus foreign patent protection in Europe, Canada, and Australia.
Cardio Flow is now working to bring this new and potentially disruptive technology to market.
A governing Board with extensive experience in the atherectomy market
Cardio Flow’s six-member Board of Directors has extensive experience in developing and bringing new medical technologies to market, including atherectomy devices.
This group includes investment executive Gary Petrucci, who founded the company that has become Cardiovascular Systems, Inc. (CSI), and Dr. Michael Kallok, who was CEO of CSI until 2007 and who took the company from start-up status to a market cap of $300 million.
Gary M. Petrucci
Chairman and Founder
Jihad A. Mustapha, M.D.
Director and Chief Medical Officer
Michael J. Kallok, Ph.D.
Steven C. Simon